Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.


This study was designed to evaluate irinotecan (CPT-11) disposition and pharmacodynamics in the presence and absence of the broad-spectrum antibiotic neomycin. Seven evaluable cancer patients experiencing diarrhea graded > or =2 after receiving CPT-11 alone (350 mg/m(2) i.v. once every 3 weeks) received the same dose combined with oral neomycin at 1000 mg… (More)


4 Figures and Tables

Slides referencing similar topics